Infusion center and rheumatology practice marketing: coverage wording, copay coupons and drug terms in ads

An infusion center, or a rheumatology practice with its own infusion suite, markets a service that is built around a prescription drug. That puts three sets of rules on the same page: what Medicare and other payers say about what a patient pays, what the HHS Office of Inspector General (OIG) says about manufacturer copay coupons and assistance programs, and what Google allows when an ad or keyword names a prescription drug. Health claims sit on top of all three.

This guide walks through each one and ends with an illustration, a checklist and answers to the questions practice owners ask. It does not name any drug or biologic, and it does not discuss which treatment suits which condition. That is a clinical decision between a patient and their clinician, not a marketing message. Centers that infuse IBD treatments should read IBD center marketing on cure and remission wording. Iron infusion claims are covered in hematology practice marketing.

What makes infusion marketing different

An infusion starts with a prescription, so the marketing question is where it is given and what it will cost. That shifts the useful message toward access, scheduling, coverage checks and comfort, and away from the drug itself.

It also means money is close to every message. Copays, coinsurance, manufacturer savings programs and charity assistance all affect what a patient pays, and each has rules about how it can be offered. A sentence that sounds like good customer service, such as “we will make sure you pay nothing”, can run into federal fraud and abuse law if it reaches Medicare or Medicaid patients.

Referring physicians are an audience too. What you can and cannot give a referral source is covered in our guide to patient and physician referrals, so this guide does not repeat it.

Describing coverage and cost accurately

Medicare.gov says Medicare Part B covers most injectable and infused drugs when a licensed medical provider gives them. It also says that in most cases, after the Part B deductible is met, the patient pays up to 20 percent of the Medicare-approved amount for Part B drugs, and that providers must accept assignment for Part B-covered drugs, so they should never ask the patient to pay more than the coinsurance or copayment for the drug itself.

The same page adds two details that matter for marketing copy. Coinsurance can be lower for certain Part B drugs whose prices have risen faster than inflation, and the list of those drugs and the savings change every quarter. When a Part B drug is given in a hospital outpatient setting as part of outpatient services, the patient pays a copayment for the services instead. So what a Medicare patient pays depends on the drug, the setting and any other coverage they have.

That makes fixed cost promises risky. Wording that stays accurate:

• “We check your coverage and estimate your share before your first infusion.” (Only if your team does this.)
• “We accept Medicare.” (Only if you are enrolled and accept assignment.)
• “Ask our financial counselor about assistance programs you may qualify for.”

Wording to avoid: “no out-of-pocket cost”, “$0 infusions” or “we cover your copay”. The first two are not true for every patient, and the third is an offer to waive cost sharing, which the next sections cover. If you publish self-pay prices, our guide to advertising cash prices covers how to keep them and their conditions honest.

Manufacturer copay coupons: what the OIG says

In a Special Advisory Bulletin dated September 2014, the OIG said that manufacturer copayment coupons are remuneration offered to consumers to induce the purchase of specific items, and that when the item can be paid for by a federal health care program, the anti-kickback statute is implicated. The bulletin defines coupons broadly: print coupons, electronic coupons, debit cards and direct reimbursements that reduce or eliminate a patient’s out-of-pocket costs for specific prescription medications.

The bulletin notes that coupons typically say they may not be used by beneficiaries of federal health care programs, and it says manufacturers may face sanctions if they fail to take appropriate steps to keep coupons from inducing the purchase of federal program items or services. It also cites the beneficiary inducement civil monetary penalty at 42 U.S.C. 1320a-7a(a)(5), which can apply where a coupon may induce a beneficiary to use a particular practitioner or pharmacy.

The bulletin is written about manufacturers and Part D, and its footnote names pharmacies that accept coupons for federal program beneficiaries as also possibly subject to sanctions. It does not name infusion centers. The anti-kickback statute at 42 U.S.C. 1320a-7b(b) applies to whoever offers, pays, solicits or receives remuneration, though, so the same caution makes sense for any site that helps patients use coupons.

For marketing, that leads to a few practical lines:

• If your website mentions manufacturer savings programs, say that eligibility is set by each program’s own terms, and that the OIG notes coupons typically say they may not be used by beneficiaries of federal health care programs such as Medicare and Medicaid.
• Do not aim coupon messages at Medicare or Medicaid patients, for example in a mailing to patients you know have Medicare.
• Do not present a manufacturer program as your own discount, and do not tie it to choosing your center.
• Keep drug names out of the ad itself. That is our own editorial choice for this guide, and it also avoids the Google rules below.

Charity assistance and your own financial help

In its Supplemental Special Advisory Bulletin on Independent Charity Patient Assistance Programs, published at 79 FR 31120 on May 30, 2014, the OIG says the principles of its earlier guidance apply regardless of which federal health care program is involved, which includes Medicare Part B. It also says a manufacturer subsidy for cost sharing may implicate the beneficiary inducement penalty if it is likely to influence a beneficiary’s choice of provider, practitioner or supplier, for example by making eligibility depend on the patient using certain prescribing physicians or certain pharmacies.

The marketing lesson is about choice. Helping a patient find out whether an independent charity can help is one thing. Advertising that assistance is available only if the patient gets treated at your center is another, and it is the pattern the OIG describes as a concern.

Your own financial help has its own rule. Under 42 U.S.C. 1320a-7a(i)(6)(A), waiving Medicare coinsurance and deductibles is not remuneration only if the waiver is not offered as part of any advertisement or solicitation, is not routine, and follows a good faith determination of financial need or reasonable collection efforts. A financial hardship policy can exist; it cannot be advertised as a waiver. Our guide to marketing to Medicare patients lists the other exceptions, including the OIG limit on gifts of nominal value.

Drug names in Google Ads

Google’s Healthcare and medicines policy restricts the promotion of services related to the online prescribing, dispensing and sale of prescription drugs, and allows pharmaceutical manufacturers to advertise prescription drugs only in select locations and with certification. Its Restricted drug terms policy says Google restricts the use of prescription drug terms in ads, landing pages and keywords.

For campaigns targeting the United States, Canada or New Zealand, the Restricted drug terms policy says advertisers may use prescription drug terms for promotional purposes in accordance with local laws, and do not need certification to use those terms in ads and landing pages. Certification is required to keyword-target those terms, and for certain business types such as online pharmacies, telemedicine providers and pharmaceutical manufacturers. Google also says not to apply for a certification category that does not match your business model. Outside those three countries, prescription drug terms may not be used in ads or landing pages.

One way to stay clear of the keyword certification question is to build search campaigns around the service and the place rather than drug names. Searches for an infusion center or infusion therapy near a city say what the patient needs without a drug term. Landing pages can describe the types of therapy you give and how the visit works, and Google’s policy is the reason to check any drug names on those pages before launch. For a wider overview, see our guide to healthcare ad policy basics.

A rheumatology practice markets more than its infusion suite. Condition pages, cure and reverse claims, diet and supplement content and biosimilar wording are covered in our rheumatology practice marketing guide.

Claims about infusion and rheumatology care

Section 5 of the FTC Act, 15 U.S.C. 45, prohibits unfair or deceptive acts or practices in or affecting commerce. The FTC Health Products Compliance Guidance is written for health products, but the same caution makes sense for services: the FTC approach generally requires that health-related claims be backed by competent and reliable scientific evidence.

Claims that tend to cause trouble in this field fall into three groups:

• Outcome promises, such as “get your life back”, “stop the flare-ups” or “remission starts here”. These describe results no center can promise every patient.
• Comparisons, such as “safer than the hospital” or “costs less than hospital infusion”. Safety comparisons need evidence for your own patients, and the Medicare.gov page above shows that costs depend on the drug, the setting and the patient’s coverage.
• Drug claims of any kind. What a drug does is set by its labeling and the prescriber, not by a center’s ad.

What you can say is the practical information a patient needs: hours, how quickly a referral can be scheduled if you track that accurately, who supervises infusions, what the chairs and rooms are like, whether there is parking and Wi-Fi, which insurers you work with, and how the team handles prior authorization. Patient stories need consent and the FTC endorsement rules; see our guide to patient testimonials and photos.

Patient messages and HIPAA

If you send patients reminders about scheduled doses, 45 CFR 164.501 treats those differently from other messages. The definition of marketing excludes refill reminders and other communications about a drug or biologic currently being prescribed for the individual, but only if any financial remuneration the covered entity receives for sending the message is reasonably related to its cost of sending it.

That line matters if a manufacturer offers to pay for a messaging program. Payment above cost turns a reminder into marketing, and marketing that involves financial remuneration needs the patient’s authorization under 45 CFR 164.508(a)(3), which must state that remuneration is involved. Our guide to HIPAA marketing rules covers authorizations and the other exceptions.

Illustration: one infusion center campaign checked against the rules

Illustration: an independent rheumatology practice opens an infusion suite and plans a launch. The plan has a service page on its website, a search campaign, a letter to referring physicians and a reminder program for current infusion patients.

• The service page describes the suite, hours, scheduling, who supervises infusions and how the team checks coverage. It names no drugs and makes no outcome or price promises.
• The page has a short section on assistance: manufacturer programs set their own eligibility and typically exclude federal program beneficiaries, and a financial counselor can help patients check what they may qualify for.
• The search campaign targets infusion center and infusion therapy searches around the practice’s location, with no drug names as keywords.
• The letter to referring physicians describes the service and how to refer. It offers nothing of value for referrals.
• Reminder messages go to current patients about their scheduled infusions. The practice accepts no manufacturer payment for them.

Checklist before an infusion campaign goes out

• Does any ad or page promise a specific out-of-pocket cost, such as $0?
• Does any message offer to waive or cover copays or coinsurance?
• Are manufacturer savings programs described as the manufacturer’s, with eligibility set by their terms?
• Could any coupon message reach Medicare or Medicaid patients?
• Is any assistance presented as available only if the patient is treated at your center?
• Do any keywords target prescription drug terms, and are you certified for that?
• Are drug names on landing pages checked against Google’s current policies?
• Are there outcome promises, safety comparisons or cost comparisons without evidence?
• Is anyone paying you to send patient messages about a drug, and has that been reviewed under 45 CFR 164.501?
• Has a qualified health care attorney reviewed anything that touches cost sharing?

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices. Our Google Ads for practices work builds campaigns around your services and location, checks restricted terms before launch, and tracks inquiries without sending health information to ad platforms. Our medical website design work can give your infusion suite a clear service page that answers the scheduling and coverage questions patients ask. We do not decide what your cost sharing policies allow; your counsel does. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it.

Frequently asked questions

Sources

• Medicare.gov: Prescription drugs (outpatient), Part B coverage and costs
• OIG Special Advisory Bulletin: Pharmaceutical Manufacturer Copayment Coupons (September 2014)
• OIG Supplemental Special Advisory Bulletin: Independent Charity Patient Assistance Programs (79 FR 31120, May 30, 2014)
• 42 U.S.C. 1320a-7a: Civil monetary penalties (subsections (a)(5) and (i)(6))
• 42 U.S.C. 1320a-7b: Criminal penalties for acts involving federal health care programs (subsection (b))
• Google Ads: Healthcare and medicines policy
• Google Ads: Restricted drug terms policy
• 15 U.S.C. 45: Unfair methods of competition and unfair or deceptive acts or practices
• FTC: Health Products Compliance Guidance (December 2022)
• 45 CFR 164.501: Definitions (marketing)
• 45 CFR 164.508: Uses and disclosures for which an authorization is required

More in Facilities, care services and pharmacy